Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
2
×
san francisco blog main
astellas pharma
atlas venture
audentes therapeutics
avapritinib
avidity biosciences
bluebird bio
blueprint medicines
cstone pharmaceuticals
deals
duchenne muscular dystrophy
dyne therapeutics
eli lilly
european medicines agency
facioscapulohumeral muscular dystrophy
fda
fisogatinib
flatiron health
gene therapy
genentech
hepatocellular carcinoma
investing
jeff albers
joshua brumm
kaleido biosciences
medullary thyroid cancer
muscular dystrophy
myotonic dystrophy type 1
new york blog main
non-small cell lung cancer
pralsetinib
rare disease drugs
What
drug
medicines
muscle
2
×
ago
approval
biotechs
blueprint
cancer
candidate
considering
currently
data
diseases
dyne
early
expected
experimental
eyes
fda
genetic
having
humans
ipo
ipos
long
marketing
pact
rare
reach
regulatory
ret
review
roche
team
therapeutics
wins
worked
Language
unset
Current search:
muscle
×
boston
×
" national top stories "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact